Improved enzyme immunoassay for human basic fibroblast growth factor using a new enhanced chemiluminescence system.
An enhanced chemiluminescence reaction has been incorporated into an enzyme immunoassay (EIA) for human basic fibroblast growth factor (hbFGF). We developed a new luminol derivative, designated L-012 and a new enhancer, 4-(4-hydroxyphenyl)thiazole. Using these compounds, the detection limit of hbFGF was improved to 0.1 pg/assay, which was 10-20 and 2 times better than the o-phenylenediamine colorimetric and luminol chemiluminescence assays, respectively. The average concentration of bFGF in sera from 25 normal volunteers was 5.9 pg/ml. On the other hand, serum bFGF levels were elevated in renal, lung and brain tumor patients. The data presented here indicate that the serum bFGF level could be a useful diagnostic marker for these tumors. Furthermore, these new compounds could easily be applied to any other EIA that uses horse radish peroxidase to improve sensitivity.
Pharmaceutical Research Division, Takeda Chemical Industries, Osaka, Japan.
M
M
Ii
H
H
Yoshida
Y
Y
Aramaki
H
H
Masuya
T
T
Hada
M
M
Terada
M
M
Hatanaka
Y
Y
Ichimori
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood*; D001932:Brain Neoplasms / Q000097:blood; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D007124:Immunoenzyme Techniques; D007202:Indicators and Reagents; D007680:Kidney Neoplasms / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood; D008163:Luminescent Measurements; D008165:Luminol / Q000031:analogs & derivatives; D008175:Lung Neoplasms / Q000097:blood; D009369:Neoplasms / Q000097:blood*; D012016:Reference Values; D013274:Stomach Neoplasms / Q000097:blood; D001749:Urinary Bladder Neoplasms / Q000097:blood
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D007202:Indicators and Reagents; D016222:Fibroblast Growth Factor 2; C081614:L 012; D008165:Luminol